TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SN1UAT8

Market Closed - Deutsche Boerse AG 01:07:04 21/06/2024 am IST
2.49 EUR +4.18% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month+48.45%
1 month+27.81%
Date Price Change
21/24/21 2.49 +4.18%
19/24/19 2.39 -4.40%
18/24/18 2.5 -3.10%
17/24/17 2.58 +4.88%
14/24/14 2.46 -0.40%

Delayed Quote Deutsche Boerse AG

Last update June 21, 2024 at 01:07 am IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SN1UAT
ISINDE000SN1UAT8
Date issued 14/06/2022
Strike 58.76 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.25
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 6.26
Lowest since issue 1.48
Spread 0.01
Spread %0.40%

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
84.15 USD
Average target price
108.1 USD
Spread / Average Target
+28.45%
Consensus